BioXcel Therapeutics (BTAI) Enterprise Value (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Enterprise Value of -$17.2 million for Q1 2026, up 44.6% year-over-year from -$11.9 million in Q1 2025, and up 40.26% quarter-over-quarter from -$28.8 million in Q4 2025.
BioXcel Therapeutics (BTAI) Enterprise Value (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Enterprise Value history runs 10 years deep, the most recent figure standing at -$17.2 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 44.6% year-over-year to -$17.2 million; the TTM figure through Mar 2026 stood at -$17.2 million (up 44.6% YoY), while the FY2025 annual figure was -$28.8 million, up 3.67% from the prior year.
- Enterprise Value for Q1 2026 stood at -$17.2 million, up from -$28.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$17.2 million in Q1 2026, with the low at -$233.5 million in Q2 2022.
- The 5-year median for Enterprise Value is -$65.2 million (2023), against an average of -$96.6 million.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value retreated 3.31% in 2022, then jumped 66.99% in 2025.
- BioXcel Therapeutics' Enterprise Value stood at -$193.7 million in 2022, then surged by 66.33% to -$65.2 million in 2023, then soared by 54.23% to -$29.9 million in 2024, then grew by 3.67% to -$28.8 million in 2025, then surged by 40.26% to -$17.2 million in 2026.
- Business Quant data shows BTAI's Enterprise Value at -$17.2 million in Q1 2026, -$28.8 million in Q4 2025, and -$37.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | -164.00 Mn |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | -13.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.80 Mn |
| Mar 31, 2026 | -17.18 Mn |
| Dec 31, 2025 | -28.76 Mn |
| Sep 30, 2025 | -37.32 Mn |
| Jun 30, 2025 | -18.58 Mn |
| Mar 31, 2025 | -31.01 Mn |
| Dec 31, 2024 | -29.85 Mn |
| Sep 30, 2024 | -40.39 Mn |
| Jun 30, 2024 | -56.27 Mn |
| Mar 31, 2024 | -74.14 Mn |
| Dec 31, 2023 | -65.22 Mn |
| Sep 30, 2023 | -89.96 Mn |
| Jun 30, 2023 | -127.55 Mn |
| Mar 31, 2023 | -165.52 Mn |
| Dec 31, 2022 | -193.73 Mn |
| Sep 30, 2022 | -232.31 Mn |
| Jun 30, 2022 | -233.45 Mn |
| Mar 31, 2022 | -200.44 Mn |
| Dec 31, 2021 | -232.97 Mn |
| Sep 30, 2021 | -252.91 Mn |